Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with idiopathic ...

Idiopathic hypersomnia is a neurological sleep disorder characterised by excessive daytime sleepiness despite getting a full ...